Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia.

Next Previous
Trial Profile

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin; Busulfan; Clofarabine; Methotrexate; Tacrolimus
  • Indications Acute biphenotypic leukaemia; Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 07 Aug 2018 Biomarkers information updated
  • 17 Jun 2013 Planned end date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
  • 17 Jun 2013 Planned number of patients changed from 100 to 150 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top